– Reuters
Processa Pharmaceuticals Provides Interim Analysis From Ongoing Phase 1b Trial Of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FUInterim analysis of the NGC-Cap Phase 1b data shows improved safety, even with 5-FU